bioRxiv
Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia
Publication
, Preprint
Kelvin, J; Zhang, D; Williams, E; Moore, S; Birnbaum, L; Zecca, H; Wang, X; Jain, J; Qui, M; Jui, N; Fu, H; Du, Y; Kemp, M; Lam, W ...
2022
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelvin, J., Zhang, D., Williams, E., Moore, S., Birnbaum, L., Zecca, H., … Dreaden, E. (2022). Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia. bioRxiv. https://doi.org/10.1101/2022.09.21.508196
Kelvin, James, Dan Zhang, Evelyn Williams, Samuel Moore, Lacey Birnbaum, Henry Zecca, Xiaodong Wang, et al. “Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia.” BioRxiv, 2022. https://doi.org/10.1101/2022.09.21.508196.
Kelvin J, Zhang D, Williams E, Moore S, Birnbaum L, Zecca H, et al. Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia. bioRxiv. 2022.
Kelvin, James, et al. “Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia.” BioRxiv, 2022. Epmc, doi:10.1101/2022.09.21.508196.
Kelvin J, Zhang D, Williams E, Moore S, Birnbaum L, Zecca H, Wang X, Jain J, Qui M, Jui N, Fu H, Du Y, Kemp M, Lam W, DeRyckere D, Graham D, Dreaden E. Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia. bioRxiv. 2022.